Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 203

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway

Open access
Hamnvik, Ole‐Petter R., Choueiri, Toni K., Turchin, Alexander, McKay, Rana R., Goyal, Lipika, Davis, Michael, Kaymakcalan, Marina D., Williams, Jonathan S.·2015·Cancer

Abstract

BACKGROUND: VEGF signaling pathway inhibitor (anti‐VEGF) therapy is associated with hypertension, but little is known about predisposing clinical characteristics. This study describes the real‐world association between baseline clinical characteristics, blood pressure (BP) response, and survival in patients prescribed anti‐VEGF therapies. METHODS: Clinical data from Partners HealthCare in Massachusetts was obtained from adults treated with anti‐VEGF therapies (2002‐2013). Treatment‐induced hypertensive response was defined as worsening of preexisting hypertension or new diagnosis of hypertension (if no prior hypertension history). RESULTS: Data from 1120 patients with renal cell carcinoma (32.2%), hepatocellular carcinoma (11.6%), gastrointestinal stromal tumors (12.5%), and other sarcomas (15.3%) were analyzed. Most patients received sunitinib (52%), sorafenib (25.9%), or pazopanib (18%). A treatment‐induced hypertensive response was identified in 49.7% of treated patients. Preexisting hypertension, present in 65.4%, was an independent risk factor for BP elevation (odds ratio [OR], 1.56; 95% confidence interval [CI], 1.27‐1.92); other risk factors included age ≥60 years (OR, 1.26; 95% CI, 1.06‐1.52), and body mass index (BMI) ≥25 kg/m 2 (OR, 1.26; 95% CI, 1.04‐1.53). Race, sex, anti‐VEGF therapy prescribed, and baseline antihypertensive class were not significant risk factors. The absolute observed mean increase in BP was 21 mm Hg (systolic)/15 mm Hg (diastolic), both in patients with and without preexisting hypertension. The development of hypertension predicted improved survival (hazard ratio, 0.76; 95% CI, 0.65‐0.89). CONCLUSIONS: Preexisting hypertension, age, and BMI identify patients at risk for significant anti‐VEGF therapy‐induced BP elevation. Hypertension appears to be a clinical biomarker of efficacy of anti‐VEGF therapies in a broad range of malignancies. Cancer 2015;121:311–9. © 2014 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.28972

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 203

Metadata

Authors
Hamnvik, O. R., Choueiri, T. K., Turchin, A., McKay, R. R., Goyal, L., Davis, M., Kaymakcalan, M. D., & Williams, J. S.
Venue
Cancer
Publisher
Wiley
Published
2014-09-18
Volume
121
Issue
2
Pages
311-319
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1544142122
Cited by
203
References
3
FWCI
6.21
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. https://app.cochat.ai/papers/10.1002/cncr.28972
The paper
Hamnvik, O. R., Choueiri, T. K., Turchin, A., McKay, R. R., Goyal, L., Davis, M., Kaymakcalan, M. D., & Williams, J. S. (2015). Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. https://doi.org/10.1002/cncr.28972

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.